To evaluate the safety and potential benefits and abciximab administered in conjunction with half-dose rt-PA in acute ischemic stroke patients.
- Abciximab (ReoPro®)Drug
Intervention Desc: Intravenous platelet aggregation inhibitor, monoclonal antibody directed against the platelet glycoprotein GP IIb-IIIa receptor
- Tissue plasminogen activator (Activase®)Drug
Other Names: rtpa Intervention Desc: Thrombolytic
Single-center, open-label, phase I, safety and efficacy study.
Patients with acute ischemic stroke were given a combination therapy of half-dose rt-PA (0.45 mg/kg) and abciximab (initial bolus of 0.25 mg/kg followed by an infusion of 0.125 µg/kg/min for 12 hours).
|Type||Measure||Time Frame||Safety Issue|
|Primary||Frequency of symptomatic intracerebral hemorrhage at 24 hours.|
|Secondary||NIHSS at discharge.|